Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
09/2011
09/22/2011US20110230552 Use of dronedarone for the preparation of a medicament for the prevention of stroke or transient ischemic attack
09/22/2011US20110230551 Withaferin a analogs and uses thereof
09/22/2011US20110230550 Compounds, compositions and methods
09/22/2011US20110230549 Pharmaceutical compositions for the treatment of pain
09/22/2011US20110230547 Potential Prognostic Markers and Therapeutic Targets for Neurological Disorders
09/22/2011US20110230546 dsRNA COMPOSITIONS AND METHODS FOR TREATING HPV INFECTION
09/22/2011US20110230545 Eml4-alk fusion gene
09/22/2011US20110230544 Modulation of c-reactive protein expression
09/22/2011US20110230543 Oligoribonucleotide inhibitors of nrf2 and methods of use thereof for treatment of cancer
09/22/2011US20110230542 Compositions and Methods for Inhibiting Expression of the PCSK9 Gene
09/22/2011US20110230541 Process for the preparation of rotigotine
09/22/2011US20110230540 Manassatin compounds and methods of making and using the same
09/22/2011US20110230539 Small Molecule Inhibitors of N-Terminus Activation of the Androgen Receptor
09/22/2011US20110230538 Pharmaceutical for use in the treatment of ureterolithiasis
09/22/2011US20110230536 Phenylpyrazole inhibitors of store operated calcium release
09/22/2011US20110230535 Imidazolinylmethyl aryl sulfonamide
09/22/2011US20110230534 Composition For Local Anesthesia
09/22/2011US20110230533 Imidazolidinedione derivatives as antimalarial agents, preparation thereof, and methods of use
09/22/2011US20110230532 Nitrooxy cycloalkane derivatives
09/22/2011US20110230531 Therapeutic compounds
09/22/2011US20110230530 Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient
09/22/2011US20110230529 Benzamide glucokinase activators
09/22/2011US20110230528 Use of Epothilone D in Treating Tau-Associated Diseases Including Alzheimer's Disease
09/22/2011US20110230527 Caspase inhibitors and uses thereof
09/22/2011US20110230526 Thiazolyl Mglur5 Antagonists and Methods for Their Use
09/22/2011US20110230525 Dual-acting antihypertensive agents
09/22/2011US20110230524 Substituted 2-(5-hydroxy-2-methyl-1h-indole-3-yl)acetic acids and ethers thereof and the use of same to treat viral diseases
09/22/2011US20110230523 Transcription factor modulating compounds and methods of use thereof
09/22/2011US20110230521 Pyrazole Compounds As CCR1 Antagonists
09/22/2011US20110230520 Nitrate derivatives of cilostazol for the treatment of vascular and metabolic diseases
09/22/2011US20110230519 Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
09/22/2011US20110230518 Oxadiazole fused heterocyclic derivatives useful for the treatment of multiple sclerosis
09/22/2011US20110230517 Calcium receptor modulating agents
09/22/2011US20110230516 CCR1 Antagonists and Methods of Use Therefor
09/22/2011US20110230515 Compounds and methods for treatment and prevention of diseases
09/22/2011US20110230514 Morphinan Compounds
09/22/2011US20110230513 Pharmaceutical compositions for treatment of parkinsons disease
09/22/2011US20110230512 Pharmaceutical Composition
09/22/2011US20110230511 Carboxamide bioisosteres of opiates
09/22/2011US20110230510 Pharmaceutical formulations containing opioid agonist, opioid antagonist and gelling agent
09/22/2011US20110230509 Methods of use for cyclopamine analogs
09/22/2011US20110230508 Novel Forms of a Fused Pyrrolocarbazole Compound
09/22/2011US20110230507 Piperidine GPCR Agonists
09/22/2011US20110230506 Predictive marker for egfr inhibitor treatment
09/22/2011US20110230505 Quinazoline inhibitors of bace 1 and methods of using
09/22/2011US20110230504 ALLEVIATING DISORDERS WITH COMBINING AGENTS THAT INCREASE EPOXYGENATED FATTY ACIDS AND AGENTS THAT INCREASE cAMP
09/22/2011US20110230503 6, 9-Disubstituted Purine Derivatives and Their Use as Cosmetics and Cosmetic Compositions
09/22/2011US20110230502 Modulation of chemosensory receptors and ligands associated therewith
09/22/2011US20110230501 Pharmaceutical compositions for the treatment of diabetes mellitus
09/22/2011US20110230500 Inhibitors of Phosphoinositide Dependent Kinase 1 (PDK1)
09/22/2011US20110230499 Hsp90 inhibitors for therapeutic treatment
09/22/2011US20110230498 Biaryl carboxamides
09/22/2011US20110230497 Biologically active amides
09/22/2011US20110230496 Novel process for preparing highly pure levocetirizine and salts thereof
09/22/2011US20110230495 1-(2-phenoxymethylheteroaryl)piperidine and piperazine compounds
09/22/2011US20110230494 Heteroaryl compounds and uses thereof
09/22/2011US20110230493 1-OXA-8-Azaspiro [4,5] Decabe-8-Carboxamide Compounds as FAAH Inhibitors
09/22/2011US20110230492 7-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors
09/22/2011US20110230491 6-substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors
09/22/2011US20110230490 Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
09/22/2011US20110230489 s-TRIAZINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME
09/22/2011US20110230488 Hybrid-ionone and curcumin molecules as anticancer agents
09/22/2011US20110230487 Arylsulfonamide ccr3 antagonists
09/22/2011US20110230486 Modulators Of HEC1 Activity And Methods Therefor
09/22/2011US20110230485 6-phenyl-pyrimidin-4-yl-(phenylamine or phenoxy) derivatives useful as modulators of nicotinic acetylcholine receptors
09/22/2011US20110230484 Pyrazolyl-pyrimidine derivatives and their use as potassium channel modulators
09/22/2011US20110230483 Pyridine and Pyrazine derivative for the Treatment of CF
09/22/2011US20110230482 Compounds modulating c-fms and/or c-kit activity
09/22/2011US20110230481 Derivatives of tetrabromobenzimidazole, a process for the preparation thereof, a pharmaceutical composition comprising the same, a method of using the same, a method for modulating or regulating serine/threonine kinases, and serine/threonine kinases modulating agent
09/22/2011US20110230480 8-heteroarylpurine mnk2 inhibitors for treating metabolic disorders
09/22/2011US20110230479 Neurotrophin mimetics and uses thereof
09/22/2011US20110230477 Compounds, pharmaceutical composition and methods for use in treating metabolic disorders
09/22/2011US20110230476 Pi3 kinase inhibitors and uses thereof
09/22/2011US20110230474 Topical antimicrobial compositions and methods of using same
09/22/2011US20110230473 Methods and Compositions for Treating Status Epilepticus and Seizures Causing Status Epilepticus
09/22/2011US20110230472 Ring-fused azole derivative having pi3k-inhibiting activity
09/22/2011US20110230471 Benzonaphtyridine compounds as inhibitors of autotaxin
09/22/2011US20110230470 Substituted pyrazolo[4,3-c]pyridine derivatives active as kinase inhibitors
09/22/2011US20110230469 Method to Determine the Risk for Side Effects of an SSRI Treatment in a Person
09/22/2011US20110230468 Fused heterocyclic compounds and uses thereof
09/22/2011US20110230467 4,6-diaminonicotinamide compound
09/22/2011US20110230466 Association of a sinus node if current inhibitor and calcium inhibitor and pharmaceutical compositions containing it
09/22/2011US20110230465 Viral polymerase inhibitors
09/22/2011US20110230464 Purine derivatives useful as p13 kinase inhibitors
09/22/2011US20110230463 2h-chromene compound and derivative thereof
09/22/2011US20110230462 Pyrrolopyrazine Kinase Inhibitors
09/22/2011US20110230461 2,3-dihydro-1h-inden-1-yl-2,7-diazaspiro[3.5] nonane derivatives
09/22/2011US20110230460 Thienotriazolodiazepine derivatives active on apo a
09/22/2011US20110230459 Lactam acetamides as calcium channel blockers
09/22/2011US20110230458 Phenyl-heteroaryl derivatives and methods of use thereof
09/22/2011US20110230457 Substituted Isoquinolinones and Quinazolinones
09/22/2011US20110230456 Nitridoosmium(VI) Complexes for Treatment of Cancer
09/22/2011US20110230455 Aqueous-based pharmaceutical composition
09/22/2011US20110230454 (aza)indole derivative and use thereof for medical purposes
09/22/2011US20110230453 Use of Female Mammal's Urine for Determination of Fetal Gender Related Characteristics
09/22/2011US20110230452 Compounds and methods for the treatment of pain and other diseases
09/22/2011US20110230451 Identification and use of compounds that affect the fidelity of eukaryotic translation initiation codon selection
09/22/2011US20110230450 Platelet-activating factor (paf) analogs and uses thereof
09/22/2011US20110230448 Treatment and/or Prevention of Non-Viral Epithelial Damage
09/22/2011US20110230447 Osteogenesis promoter comprising [4-(methylthio)phenylthio]methanebisphosphonic acid or pharmaceutically acceptable salt thereof as active ingredient